Losartan improves heart function and decreases serum uric acid level in chronic heart failure patients

Objective To investigate the efficacy of losartan on the improvement of heart function and its effect on uric acid in patients with chronic heart failure (CHF). Methods Eighty-five patients with CHF were divided into two groups randomly. Routine anti-CHF treatment included cardiotonic, diuresis, isosorbide dinitrate, beta-blockers. In losartan group(n=43), patients were given routine anti-CHF treatment and losartan. The patients in control group(n=42) were treated by routine anti-CHF treatment and Benazapril. The heart functional was evaluated. The content of serum uric acid, electrocardiogram, and Duppler ultransonography were measured before and after treatment respectively. Results The variance of heart function, left ventricle diastoic diameter (LVDD), left ventricle ejection fraction (LVEF) and cardiothotic ratio did not show statistical difference. However, they were improved sharply as compared with base-line condition in both groups after 3 months and 12 months treatment(P0.01). Although the level of serum uric acid was decreased than base-level in both group after 12 months, but the significant change was found only in the losartan group (P0.01). Conclusion Losartan is effective and safe for the treatment of chronic heart failure with reducing serum uric acid.